Last reviewed · How we verify
NCT05157412
Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps
Phase 3 trial testing Doxycycline 100 mg Oral Tablet in Nasal Polyps in 60 participants. Completed in 1 January 2024.
1 September 2023
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 July 2021 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Doxycycline 100 mg Oral Tablet — full drug profile →
- Prednisolone 20 mg — full drug profile →
Conditions studied
- Nasal Polyps — all drugs for Nasal Polyps →
- Chronic Rhinosinusitis With Nasal Polyps — all drugs for Chronic Rhinosinusitis With Nasal Polyps →
Sponsor
Assiut University
Who can join
Adults 18 to 80, any sex, with Nasal Polyps or Chronic Rhinosinusitis With Nasal Polyps. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy of Doxycycline as an adjunct to systemic steroids in the treatment of chronic rhinosinusitis with nasal polyps
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05157412
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasal Polyps
Currently open trials in the same condition.
- NCT07245329 — Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps · NA · recruiting
- NCT07268313 — Complete Remission After Treatment With Biologics for Nasal Polyps · Phase 4 · recruiting
- NCT05575037 — Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease · Phase 2 · active not recruiting
- NCT05094570 — Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP · Phase 4 · recruiting
- NCT05287841 — Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction? · NA · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05157412 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 13 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05157412.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing